BioCardia Announces Positive CardiAMP Chronic Myocardial Ischemia Trial Results at EuroPCR
BioCardia, Inc. (Nasdaq: BCDA), a leading developer of cell-based therapies for cardiovascular diseases, has released a significant update that may be of keen interest to investors and shareholders. The company announced the oral presentation of results from its CardiAMP Cell Therapy in Chronic Myocardial Ischemia (CMI) Trial at EuroPCR, a major interventional cardiovascular medicine conference held in Paris. The presentation was delivered by Dr. Amish Raval, M.D., Professor of Medicine at the University of Wisconsin School of Medicine and Public Health, on behalf of the CardiAMP CMI Investigators.
Key Highlights from the Report
- Durable Improvements in Exercise Tolerance and Angina Reduction: The preliminary open-label cohort demonstrated that patients treated with minimally invasive CardiAMP Cell Therapy experienced significant and sustained improvements in exercise tolerance.
- Angina Episodes Reduced: Angina episodes were reduced by an average of 82% within six months after treatment, and these improvements persisted for the entire two-year follow-up period.
- Safety Profile: The procedure was well tolerated, with no treatment-emergent safety concerns reported during the study period.
- Regulation FD Disclosure: The company specifically filed this information under Regulation FD, emphasizing its importance and potential impact on investors.
- Press Release Attached: BioCardia included a press release as Exhibit 99.1 to its Form 8-K filing, reaffirming the durability of the positive results and highlighting the company’s ongoing clinical progress.
Potential Price-Sensitive Information
- The magnitude and durability of the angina reduction (82% at six months, sustained for two years) indicates a potentially transformative treatment for patients with chronic myocardial ischemia, a population with limited options. This efficacy could drive commercial interest and future partnerships, positively affecting BioCardia’s valuation.
- The strong safety profile—no treatment-emergent adverse effects—significantly de-risks the CardiAMP Cell Therapy and increases its potential for regulatory approval and broader adoption.
- The presentation at EuroPCR, one of the world’s premier cardiovascular conferences, raises BioCardia’s visibility within the medical and investment communities, potentially attracting new investors and strategic collaborators.
- The company’s explicit statement that the information furnished under Item 7.01 (Regulation FD Disclosure) is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference in future filings, underscores the immediate relevance and materiality of these clinical results for investors.
Details for Investors
- Company Details: BioCardia, Inc. (Nasdaq: BCDA), headquartered at 320 Soquel Way, Sunnyvale, CA 94085. EIN: 23-2753988. Main contact phone: 650-226-0120.
- Trial Details: CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial, open-label preliminary cohort, two-year follow-up, presented at EuroPCR by Dr. Amish Raval.
- Stock Information: Common Stock (par value \$0.001), trading symbol BCDA, listed on Nasdaq Capital Market.
- Leadership: Report signed by Peter Altman, Ph.D., President and Chief Executive Officer.
- Investor Contacts:
- Media Contact: Miranda Peto, Investor Relations ([email protected], 650-226-0120)
- Investor Contact: David McClung, Chief Financial Officer ([email protected], 650-226-0120)
Forward-Looking Statements
BioCardia cautions that forward-looking statements are not guarantees of future performance, and actual results may differ materially due to factors such as liquidity position, ability to raise additional funds, and successful advancement of clinical trials. Additional risk factors are disclosed in the company’s Form 10-K and subsequent 10-Q filings.
Conclusion
Investors should take note: The positive and durable clinical results, combined with a strong safety profile and high-profile scientific presentation, represent a major milestone for BioCardia. These developments have the potential to significantly impact the company’s share price, pending further clinical progress and regulatory milestones.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. BioCardia’s forward-looking statements are subject to uncertainties and risks as described in its SEC filings. Investors are advised to conduct their own due diligence and consult professional financial advisors before making investment decisions.
